Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
71. |
ECCT/10/03/03 | High-Dose Fluconazole Treatment in AIDS-Associated CM A5225/HiFLAC: A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) |
11-05-2012 |
View |
72. |
ECCT/11/10/01 | A RANDOMIZED PHASE IIA TRIAL OF GEMCITABINE COMPARED WITH BLEOMYCIN PLUS VINCRISTINE FOR TREATMENT OF KAPOSI’S SARCOMA IN PATIENTS ON COMBINATION ANTIRETROVIRAL THERAPY IN WESTERN KENYA. |
Principal Investigator(s) 1. NAFTALI WISINDI BUSAKHALA Site(s) in Kenya MOI UNIVERSITY CLINICAL RESEARCH SITE |
20-07-2011 |
View |
73. |
ECCT/20/07/01 | Convalescent plasma trial A randomized control trial comparing convalescent plasma therapy plus standard treatment versus standard treatment alone in patients with severe COVID-19 pneumonia at a tertiary hospital |
Principal Investigator(s) 1. Dr Isaac Adembesa Kadambi Site(s) in Kenya Kenyatta University Teaching Referral and Research Hospital |
25-09-2020 |
View |
74. |
ECCT/20/08/04 | LOW DOSE RADIATION THERAPY A pilot phase Ib/II study of whole-lung low dose radiation therapy (LDRT) in the treatment of severe Covid 19 pneumonia patients on (or requiring) mechanical ventilatory support |
Principal Investigator(s) 1. PROF. MANSOOR SALEH Site(s) in Kenya Aga Khan University Hospital, Nairobi |
11-11-2020 |
View |
75. |
ECCT/17/06/02 | PAINT Study A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years |
Principal Investigator(s) 1. Isaac Tsikhutsu Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county) 2. KAVI Institute of Clinical Research (Nairobi City county) |
10-10-2017 |
View |
76. |
ECCT/21/09/03 | Women TDF/FTC Benchmark Study Pharmacology of TDF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender Women |
Principal Investigator(s) 1. Nelly Mugo Site(s) in Kenya KEMRI-CCR PHRD (THIKA) PROJECT |
19-12-2021 |
View |
77. |
ECCT/14/11/02 | A5297 An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and < 500 cells/mm3 |
Principal Investigator(s) 1. VICTOR AKELO Site(s) in Kenya KEMRI/CDC CLINICAL RESEARCH CENTRE |
02-02-2015 |
View |
78. |
ECCT/23/11/06 | MPZ-MAL-01 A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. AHERO CLINICAL TRIALS UNIT (Kisumu county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 3. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county) |
05-02-2024 |
View |
79. |
ECCT/22/10/05 | Agios Study A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020 |
Principal Investigator(s) 1. Videlis N Nduba Site(s) in Kenya 1. KEMRI/CRDR (Nairobi City county) 2. KEMRI Siaya Clinical Research Annex (Siaya county) |
26-02-2023 |
View |
80. |
ECCT/25/09/03 | PRESERVE Partial breast re-irradiation using ultra hypofractionation (PRESERVE) Phase 2 multi-institutional study |
Principal Investigator(s) 1. Angela Waweru Site(s) in Kenya Aga Khan University Hospital |
09-02-2026 |
View |